Quarterly report · Q3
6323.TEDINET S100SLJI
Period2023-03-01 → 2023-11-30
Filed2024-01-15
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥65.2bn | 2023-03-01 → 2023-11-30 | Cons. | Net sales |
| Revenue | ¥94.5bn | 2022-03-01 → 2023-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥71.4bn | 2022-03-01 → 2022-11-30 | Cons. | Net sales |
| Operating income | ¥15.8bn | 2023-03-01 → 2023-11-30 | Cons. | Operating income |
| Operating income | ¥17.7bn | 2022-03-01 → 2022-11-30 | Cons. | Operating income |
| Ordinary income | ¥21.3bn | 2023-03-01 → 2023-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥30.3bn | 2022-03-01 → 2023-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥26.7bn | 2022-03-01 → 2022-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥21.3bn | 2023-03-01 → 2023-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥26.7bn | 2022-03-01 → 2022-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥15.5bn | 2023-03-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥21.4bn | 2022-03-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥19.7bn | 2022-03-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥15.9bn | 2023-03-01 → 2023-11-30 | Cons. | Profit loss |
| Net income | ¥20.6bn | 2022-03-01 → 2022-11-30 | Cons. | Profit loss |
| Total assets | ¥153.6bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥126.5bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥126.7bn | at 2022-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥56.6bn | at 2023-11-30 | Cons. | Liabilities |
| Total liabilities | ¥51.7bn | at 2023-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥97.0bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥74.8bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥74.4bn | at 2022-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥36.7bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥28.3bn | at 2023-02-28 | Cons. | Cash and deposits |
| EPS (basic) | ¥879.05 | 2023-03-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥320.81 | 2023-09-01 → 2023-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1,237.42 | 2022-03-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1,138.05 | 2022-03-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥422.44 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥877.43 | 2023-03-01 → 2023-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥1,235.1 | 2022-03-01 → 2023-02-28 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥1,135.91 | 2022-03-01 → 2022-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 58.3% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.9% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.0% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2023-11-30 | −¥6m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2023-11-30 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2023-11-30 | −¥432m |
| jpcrp040300-q3r_E02328-000Life Sciencereportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥300m |
| jpcrp040300-q3r_E02328-000Life Sciencereportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥300m |
| jpcrp040300-q3r_E02328-000Life Sciencereportable segment | segment profit | 2023-03-01 → 2023-11-30 | −¥115m |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥64.9bn |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥64.9bn |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥6m |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥16.3bn |
| —segment total | revenue | 2023-03-01 → 2023-11-30 | ¥65.2bn |
| —segment total | revenue external | 2023-03-01 → 2023-11-30 | ¥65.2bn |
| —segment total | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥6m |
| —segment total | segment profit | 2023-03-01 → 2023-11-30 | ¥16.2bn |
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-11-30 | −¥14m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-11-30 | −¥14m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-11-30 | −¥495m |
| jpcrp040300-q3r_E02328-000Life Sciencereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥248m |
| jpcrp040300-q3r_E02328-000Life Sciencereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥248m |
| jpcrp040300-q3r_E02328-000Life Sciencereportable segment | segment profit | 2022-03-01 → 2022-11-30 | −¥116m |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥71.1bn |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥71.1bn |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥14m |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥18.4bn |
| —segment total | revenue | 2022-03-01 → 2022-11-30 | ¥71.4bn |
| —segment total | revenue external | 2022-03-01 → 2022-11-30 | ¥71.4bn |
| —segment total | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥14m |
| —segment total | segment profit | 2022-03-01 → 2022-11-30 | ¥18.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 357
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |